对硼替佐米治疗多发性骨髓瘤2/3期试验中3954例患者的回顾性分析:旨在为蛋白酶体抑制治疗多发性骨髓瘤的心脏安全性提供基准
该回顾性分析利用1项2期和7项3期研究共2509例硼替佐米治疗和1445例非硼替佐米对照的多发性骨髓瘤患者数据,评估心脏安全性终点。结果显示硼替佐米组心脏事件发生率低,与对照组无显著差异,仅水肿发生率较高,逻辑回归未显示硼替佐米增加心脏风险。
要点
- 硼替佐米治疗组≥3级充血性心力衰竭发生率为1.3-4.0%(复发/难治)和1.2-4.7%(初治)。
- 心律失常、缺血性心脏病和心脏死亡发生率低,硼替佐米组与对照组无差异。
- 一项研究和汇总移植分析中硼替佐米组水肿(多为1/2级)发生率较高。
核心结论
- 基于硼替佐米的治疗与低心脏事件发生率相关。
研究设计与样本
- 回顾性分析,利用1项2期和7项3期研究中的患者水平数据,纳入2509例硼替佐米治疗患者和1445例非硼替佐米对照方案患者。
主要发现
- ≥3级充血性心力衰竭发生率在复发/难治性多发性骨髓瘤研究中为1.3-4.0%,在初治多发性骨髓瘤中为1.2-4.7%(所有级别为2.0-7.6%),对比研究中硼替佐米组与非硼替佐米组无显著差异。
- 心律失常发生率(≥2级1.3-5.9%;≥3级0.6-4.1%)、缺血性心脏病(所有级别1.2-2.9%;≥3级0.4-2.7%)和心脏死亡(0-1.4%)均低,硼替佐米组与非硼替佐米组无差异。
- 在一项研究和一项汇总移植研究分析中,硼替佐米组比非硼替佐米组观察到更高的水肿发生率(多为1/2级)。
- 对比研究的逻辑回归分析显示,硼替佐米组与非硼替佐米组相比对心脏风险无影响。
关键数值与推荐
- 主要心脏终点包括充血性心力衰竭、心律失常、缺血性心脏病和心脏死亡,次要终点包括高血压、呼吸困难和水肿,基于MedDRA v16.0首选术语定义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This retrospective analysis aimed to establish the overall cardiac safety profile of bortezomib using patient-level data from one phase 2 and seven phase 3 studies in previously untreated and relapsed/refractory multiple myeloma (MM). Seven clinically relevant primary [congestive heart failure (CHF), arrhythmias, ischaemic heart disease (IHD), cardiac death] and secondary (hypertension, dyspnoea, oedema) cardiac endpoints were defined based on MedDRA v16.0 preferred terms. 2509 bortezomib-treated patients and 1445 patients in non-bortezomib-based control arms were included. The incidence of grade ≥3 CHF was 1·3-4·0% in studies in relapsed/refractory MM and 1·2-4·7% in previously untreated MM (2·0-7·6% all grades), with no significant differences between bortezomib- and non-bortezomib-based arms in comparative studies. Incidences of arrhythmias (1·3-5·9% grade ≥2; 0·6-4·1% grade ≥3), IHD (1·2-2·9% all grades; 0·4-2·7% grade ≥3) and cardiac death (0-1·4%) were low, with no differences between bortezomib-based and non-bortezomib-based arms. Higher rates of oedema (mostly grade 1/2) were seen in bortezomib-based versus non-bortezomib-based arms in one study and a pooled transplant study analysis. Logistic regression analyses of comparative studies showed no impact on cardiac risk with bortezomib-based versus non-bortezomib-based treatment. Bortezomib-based treatment was associated with low incidences of cardiac events.
引用
- Laubach JP, Moslehi JJ, Francis SA, et al. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017. PMID: 28466536. doi:10.1111/bjh.14708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。